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The mammalian gastrointestinal tract is continuously vulnerable to
numerous bacteria and food additives as well as to environmental toxins that damage the epithelia of the gut [1]. Disturbance in intestinal
homeostasis triggers a pathogenic immune response commonly known
as inflammatory bowel disease (IBD) [2]. IBD is a complex idiopathic disorder including clinical Crohn’s disease (CD) and ulcerative colitis (UC),
which are characterized by chronic inflammation in the mucosal layer of
the gut, which sometimes affects the whole intestine with numerous etiological manifestations [3, 4]. IBD is clinically manifested with diarrhea
and rectal bleeding accompanied by mucous pus [5] and is commonly
associated with childhood, which includes symptomatic manifestations
such as abdominal cramps, and excessive weight loss [6]. A large number
of people annually are diagnosed with IBD, a major health issue in western societies that affects around 1.4 million patients with an incidence
rate of 29.6 in 100,000 which includes clinical complexities with poorly
effective treatment regimens [7]. Moreover, multiple comorbidities that
exaggerate IBD pathogenesis include genetic predisposition, immunological disorders, a high-fat diet, and regular use of antibiotics [8].
The IBS pathophysiology is still unclear but involves the disruption of
the mucinous layer, which serves as the primary defense line of the gut
immune system and provides a physical barrier between the immune
cells of the host and synthesis of antimicrobial peptides. Additionally,
levels of colonic mucin-2 are decreased and altered during IBS [9]. This
damage further facilitates increased permeability of epithelium of gut
mucosa and alters the tight junctions, which ultimately lead to the uptake of luminal antigens [10].
The animal model for IBS exhibits many similar characteristics to human studies, which include diarrhea-associated inflammation, weight
loss, immune cell infiltration, and activation with altered macrophage
functions [11]. The most suitable and commonly used animal model to
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study experimental colitis is induced by administering dextran sodium sulfate (DSS), a chemical
colitogen with anticoagulant properties, to understand IBD pathogenesis [12]. DSS is a toxic
reagent that triggers damage in the colonic mucosa and provokes an inflammatory response [6].
DSS-induced intestinal inflammation in IBD is unclear but its multi-mechanistic pathological cascade is linked to disruption of the monolayer lining in the large intestine with distribution to the
rectum and entire colon [12]. Moreover, it disrupts
the epithelial layer of the colon, which recruits
inflammatory cells and accelerates the excessive
release of pro-inflammatory cytokines such as tumor necrosis factor-α (P-JNK-α), and interleukins
1β and 6, which leads to necrosis [13, 14]. The
DSS-induced IBS model in the research holds relevance due to its simplicity, rapidity, reproducibility,
and constructability in animal studies, and it signifies the relapse of intestinal inflammation through
adjustment of DSS concentration and variability
in the frequency of dosage administration [12].
Therefore, IBS induced through DSS is considered
a requisite tool in the identification of underlying
pathological cascades and pathways in IBS and
identification of novel therapeutic targets. Several therapeutic agents have been developed for
treatment of IBD. However, the results in efficacy are still unsatisfactory including side effects of
systemic medications and complications of drugs
[15, 16] which potentiate the need for alternate
therapy.
Ibrutinib is a novel therapeutic inhibitor of
BTK which is approved for the treatment of several disorders such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma [17, 18]. It
is also involved in the treatment of hematological
malignancies such as chronic lymphocytic leukemia, specific lymphomas [19], and Wald Enstrom’s
macroglobulinemia. Ibrutinib is recognized as the
first BTK inhibitor that has been approved by the
food and drug regulatory authority [20]. As per
our literature survey, there are fewer studies on
the role of ibrutinib in gastrointestinal disorders;
therefore in this study we investigated the pathophysiology of DSS-induced IBD and possible protective effect of ibrutinib to attenuate IBD induced
necrosis.
DSS (Catalog No: ALDRICH_42867) was purchased from Med Chem Express USA, ibrutinib
(Catalog No: W224511) was purchased from Sigma Laboratories (Sigma-Aldrich, United States),
mesalazine (Catalog No: PHR10999) from Pharmedic Laboratories, Private Limited Lahore,
Pakistan. Phosphate buffer saline tablets and
proteinase K (Catalog No: SAB4700839) were
obtained from (MP Bio, United States). Formaldehyde, hydrogen peroxide (H2O2), reduced
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glutathione (GSH), glutathione S-transferase
(GSTs), catalase, trichloroacetic acid, CDNB,
ethanol, xylene, hematoxylin, and eosin stains
were purchased from Sigma-Aldrich, United
States. Primary antibody P-NF-κB (SC-271908),
p-PI3K (SC-293115), p-AKT (SC-7985), p-GSK3β
(SC-11757), p-JNK (SC-6254), TNF-α (SC-52B83),
COX-2 (SC-514489) and other immunohistochemistry-related consumables, such as AB and
C Elite kit (two vials-SC-2018) and 3,3-diaminobenzidine (DAB) (SC-216567), were provided by
Santa Cruz Biotechnology, USA. The biotin secondary antibody (ab-6789) and DPX mounting
media were purchased from Abcam UK.
Seventy healthy male adult Albino mice having weight 35 ±15 g, and 8–12 weeks of age, obtained from the local breeding facility of Riphah
International University Islamabad, were randomly divided into five groups (14 mice/group). The
mice were placed in plastic cages and held at room
temperature 18–22°C, with a light/dark cycle of
12 h. Throughout the experiment, animals were
given free access to rat pellet diet ad-libitum and
tap water. For the entire duration of the research,
animals were kept under continuous surveillance.
To keep the mice free from stress, all appropriate managerial procedures were adopted. Prior
approval was obtained for all such experimental
protocols from the Research and Ethical Committee (REC) of Riphah Institute of Pharmaceutical
Sciences (RIPS), Riphah International University,
Pakistan. Mice were randomly divided into five experimental groups, i.e., control group (saline), disease group (DSS-3%), standard group (mesalazine
10 mg/kg), treatment group 1 (ibrutinib 6.25 mg),
and treatment group 2 (ibrutinib 12.5 mg), and
these doses were selected as in previous literature [21, 22]. A total of 15 animals died during the
experimental procedure due to excessive bleeding
in feces and dehydration, i.e., 6 from the disease
group, 2 from the mesalazine group, and 2 from
both ibrutinib groups.
To avoid a potential impact, colitis-induced
mice and their littermates were co-housed and acclimatized for over a week. Colitis was induced in
mice following the protocol published before [23].
Briefly, mice (male, 8–12 weeks old) fed a normal
diet were administered 3% dextran sulfate sodium salt (DSS) (MW 36–50 kDa; MP Biomedical,
Irvine, CA, USA) dissolved in drinking water for
10 days. Control littermates were given regular drinking water. During induction, mice were
weighed and stools were tested for occult blood
daily to assess pathology severity. At the end of induction time points, mice were euthanized by CO2
inhalation. Colon and other tissue were collected
and snap-frozen in liquid nitrogen and stored at
–80°C for further use. Blood was centrifugated in
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1000 g for 30 min at 4°C to isolate serum. The
serum was stored at –80°C for further use as well.
The course of inflammation was monitored
by weight loss measurements and the stool morphology test. Pathological scoring was used to
quantify the severity of colitis following a method adapted from the standard DAI scoring system
[24]. Each animal was examined once a day and
received a score containing three parameters,
body weight decreasing, fecal bleeding, and stool
consistency. For the assessment score, the definition was as follows: the decrease in body weight
relative to initial weight reached 0–1% scored 0,
1–5% scored 1, 5–10% scored 2, 10–15% scored
3 and over 15% scored 4; the stool normal and
no blood scored 0, a dimly visible streak of blood
scored 1, moderate blood scored 2, obvious blood
scored 3 and gross bleeding from the anus scored
4. As for the stool viscosity, normal, the score of
0; soft, 1; loss, 2; diarrhea, 3 and diarrhea with
blood, 4. Then these features were averaged for
each mouse and each group to calculate the percentage of diarrhea.
Mice were subjected to fasting condition for 8 h
before blood collection. The blood sample was collected on day one via the tail vein to measure the
levels of liver enzymes. At the end of the study
period i.e., the 10th day, mice were anesthetized
and blood samples were collected by direct cardiac puncture using a 3 ml BD syringe. For serum
biochemistry, blood was collected in clotted tubes,
blood was permitted to clot at 26 ±2°C, serum
was extracted by centrifugation at 3000 RPM for
10 min. After obtaining blood samples, all mice
were euthanized and the sample was processed.
Blood samples drawn from cardiac punctures,
collected in clotted vials, were utilized for estimation of serum biochemical parameters. Biochemical assays of serum were performed using biochemical assay kits (TB, ALT, ALP, AST) on
a biochemistry analyzer (Beckman Coulter AU480,
USA). All procedures were conducted in compliance with the manufacturer’s protocol.
The collected samples were fixed in 4% formaldehyde and decalcified using nitric oxide. The
histological samples after the gross study were
embedded in paraffin blocks, cut into 4 μm thin
sections using a microtome, and the following
analysis was performed.
H& E staining was performed as mentioned in
our previous paper. Absolute xylene (100%) was
used to de-paraffinize the tissue sections on coated slides, rehydrated with ethyl alcohol from 100%
to 70%. Following washing with distilled water,
slides were incubated in hematoxylin solution for
10 min (depending upon the nature of the hematoxylin stain). The hematoxylin stain was recycled
and slides were put into low-speed tap water, sub-

sequently dipped for one gentle treatment with 1%
HCl and 1% ammonia water. The slides were finally
incubated with eosin and kept for air drying. The
dried slides were processed with the dehydration
protocol and mounted with a glass coverslip. Histological assessment was performed under a light
microscope for measuring villus heights (from villus
tip to villus-crypt junction), crypt depth (invagination depth between adjacent villi), crypt cell apoptosis, and mitotic indexes. Twenty well-oriented villi
and crypts for villus height, crypt depth, and mitotic
figures per crypt were measured and scored for the
average of each sample. All intestinal morphometric assessment was performed blindly by ImageJ
software 1.8_172 (NIH, USA).
With slight modifications, immunohistochemical staining was performed as previously described.
To retrieve the antigen, the slides were subjected to
proteinase K treatment and then washed with PBS
and the peroxidase activity was further quenched.
Slides were blocked with normal goat serum (NGS)
and incubated overnight in mouse anti-nuclear factor-κB (NF-κB), mouse anti-COX2 (dilution
1 : 100, Santa Cruz Biotechnology, United States),
and mouse anti-nuclear p-JNK (dilution 1 : 100,
Santa Cruz Biotechnology, United States). After
washing, secondary antibodies (dilution 1 : 50)
were applied in a humidified chamber, and then
ABC reagent (SCBT, United States) was applied. After washing, slides were stained by DAB and coverslipped with a mounting medium. ImageJ software
was used to quantitatively determine hyperactivated COX2, p-JNK, and p-NF-κB in the intestine/
total area by optimizing the background of images
according to the threshold intensity and analyzing COX2, p-JNK, and p-NF-κB positive cells at the
same threshold intensity for all groups. The intensity is expressed as the relative integrated density
of the samples relative to the control.
All the samples were homogenized using lysis
buffer (1M Tris-HCl, 5 M NaCl, sodium deoxycholate 0.5%, sodium dodecyl sulfate 10%, sodium
azide 1%, and NP-40 10%) further supplemented
with a protease inhibitor, i.e. phenyl methyl sulfonyl fluoride (PMSF). After sonification and centrifugation, the protein concentration of the lysate
was determined using a Bicinchoninic Acid kit
(BCA) (Pierce, Rockford, IL, United States) following the guidelines of the manufacturer. An equal
amount of protein (30 µg per sample) was electrophoresed on 10% SDS-PAGE gels, followed by
transferring the protein to polyvinylidene fluoride
(PVDF) membranes (Millipore, Billerica, MA, United States). After blocking the PVDF membranes
using skim milk to reduce binding of the nonspecific protein, the PVDF membrane was incubated
at 4°C for the whole night with the primary antibodies COX2, p-NF-κB, TNF-α, p-Akt, p-PI3K, and
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p-GSK3β. β-actin was used as a loading control.
The following day, membranes were incubated
with secondary antibodies, and western bands
were visualized on X-ray film using an ECL detection reagent following the instructions of the
manufacturer (Amersham Pharmacia Biotech, Piscataway, NJ, United States). Image J software was
used for the analysis of WB bands and was analyzed relative to β-actin.
Our laboratory protocols were adopted for
these assays. Briefly, the glutathione (GSH) level [25] for measuring catalase and glutathione
S-transferase (GST) activity was analyzed according to the procedure described by Rahman et al.
(2020) [26].
The method mentioned previously was used
to determine lipid peroxidation [27]. Mice intestinal tissue was homogenized by the aid of a polytron homogenizer in 20 mM Tris HCl. Following
supernatant collection, ferrous ammonium sulphate was added to the clear supernatant incubated at 37°C to calculate lipid peroxidation. Later
on, 2-thiobarbituric acid (TBA) was added to the
above mixture and the absorbance was calculated
at 532 nm by employing a microplate reader.
Morphological data were analyzed using ImageJ software (NIH Image J system, Bethesda,
MD). The results were expressed as mean ± standard error of the mean (SEM, n = 5) and statistically analyzed via one-way analysis of variance
(ANOVA) followed by Tukey’s post-hoc test. Values
of p < 0.05 were considered as statistically significant. GraphPad Prism (GraphPad, San Diego, CA,
USA) was used for analysis of data.
Mice in all 5 groups were examined for physical and pathological symptoms of IBD including
weight loss, food intake, and diarrheal tendency.
Mice in the saline group showed normal locomotion, eating, and drinking behavior with no signs
of diarrhea or weight loss compared to the DSS
group with a decline in physical assessment accompanied with bloody diarrhea (Figures 1 A–C).
Mice treated with ibrutinib at a dose of 6.25 mg/
kg improved reluctance to movements and food
intake with increased weight and less watery
stools (Figures 1 A–C). However, ibrutinib at a dose
of 12.5 mg/kg significantly attenuated diarrhea
and weight loss in DSS-induced IBD, suggesting
its dose-dependent effect. Mesalazine (10 mg/kg)
showed a marked effect on physical symptoms including weight loss, diarrhea, and movement as
compared to the DSS group (Figures 1 A–C).
The saline group showed no pathological changes and normal architecture of both small and large
intestinal tissues (Figure 2 A). In the DSS group,
significant alterations were observed including epithelial destruction, inflammatory infiltration, and
crypt damage, which are key indicators of colon
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tissue injury (Figures 2 A, B). In the 6.25 mg treated ibrutinib group, moderate inflammatory cells
were noted, which can result in inflammation and
edema formation (Figure 2). A significant protective effect was observed for ibrutinib at a dose of
12.5 mg, with no visualization of inflammatory
cells, no evidence of crypt cell damage, further validated by no fissures on colon and intestinal cells,
indicating normal architecture of colon tissues similarly to the control group. Some mild inflammatory
cells were observed in the standard group (mesalazine 10 mg/kg) but no epithelial damage in extraand intracellular spaces was found (Figures 2 A, B).
The expression of inflammatory mediators in
intestinal cells was determined using immunohistochemistry and western blot for expression
analysis of molecular markers of inflammation.
Compared with baseline expression, the levels of
TNF-α, p-NF-kB, and COX2 were significantly increased in the disease group as shown in Figure 3 A
(*p < 0.05) in comparison to control. To further validate this, we performed immunohistochemistry
and similar results were obtained (Figures 3 B, C).
Treatment with ibrutinib significantly ameliorated the elevated inflammatory markers. Moreover,
p-NF-κB is linked to downstream inflammatory cytokines; therefore we sought to determine whether ibrutinib could affect p-JNK level. An elevated
level of P-JNK in the disease group was noted
compared to that in the control group as shown
in Figure 3 D while treatment with ibrutinib attenuated this elevated level of p-JNK relative to the
disease group (Figure 3 D, #p < 0.05).
Western blot analysis was performed to determine the effect of ibrutinib on the PI3K/Akt pathway (Figure 4). DSS reduced the expression level
of these protective markers (*p < 0.05) while treatment with ibrutinib reversed the downexpression
of these proteins and similar results were obtained as that of the standard (Figure 4, #p < 0.05).
As first-line indicators of oxidative damage, the
levels of enzymatic and non-enzymatic oxidants
such as GST and GSH were measured in intestinal
tissues on the 3rd, 6th, and 10th day. Administration
of DSS induced reactive oxygen species (ROS)
along with the exhaustion of GSH and GST in
the intestinal tissue homogenates (Figure 4 A, B).
Treatment with ibrutinib increased the levels of
GSH and GST in the intestine homogenates. Further, treatment with ibrutinib restored the level of
CAT in both homogenates (Figure 4 C). Oxidative
stress and ROS generated in hyperuricemia induced the formation of several detrimental products, including malondialdehyde (MDA), which
can be measured by TBARS. Therefore, we performed a lipid peroxidation (LPO) assay to assess
the degree of damage induced by LPO products,
which were increased relative to the saline group
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(Figure 4 D). Ibrutinib and mesalazine treatment
attenuated LPO in the intestinal tissue (Figure 4 D).
DSS induces dramatic changes in levels of enzymatic enzymes such as ALP, ALT, AST, and TB.
Levels of liver enzymes were examined on the 3rd,
6th and 10th days of treatment. Normal levels of liver enzymes were detected in the saline group as
compared to the DSS group on the 3rd, 6th, and 10th
day respectively (Table I). However, ibrutinib (6.25,
12.5 mg/kg) significantly attenuated the levels of
ALP, ALT, ASP, and TB, showing a potent effect on
liver enzyme levels (Table I). Mesalazine (10 mg/
kg) showed an effect on liver enzymes by attenuating levels of liver enzymes (Table I).
In the current study, we investigated the protective effects of ibrutinib against DSS-induced
IBD, which was mediated possibly by attenuating
the oxidative and inflammatory cascade as ibrutinib exhibited anti-inflammatory potential in the
previous studies [28]. Several studies supported
the immunomodulatory role of ibrutinib and we
further investigated the role of the favorable bi-
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Figure 1. Ibrutinib attenuated physical manifestations of DSS-induced IBD in mice. A – Diarrhea
score. B – Food intake. C – Body weight changes.
Data show the percent incidence of diarrhea at different time intervals. The severity of diarrhea is evident from 72 h (day 3) to 240 h (day 10) after DSS
administration. As compared to the DSS group,
ibrutinib (6.25 mg and 12.5 mg) pretreatment
reduces this severity from 120 h (day 5) to mild
and moderate type. All the mice were monitored
during the whole experiment for diarrhea score,
which was based on stool consistency. The data
are expressed as mean ± SEM and were analyzed
using one-way ANOVA followed by Tukey’s multiple comparison test, and n = 14/group. The symbol
* shows a difference relative to the saline group
and # shows a difference relative to the DSS group.
The data presented are relative to saline and the
disease group. The symbols *** and ### represent
significant difference values of p < 0.001, while the
symbol ## represents p < 0.01 values for significant
differences and # represents p < 0.05

ological effects of ibrutinib, and we observed
a dose-dependent response and the results are
comparable to the standard group. Our study
showed that ibrutinib treatment restored the
physical parameters of colitis such as acute diarrhea, diminished water, and food intake, recovered the structural integrity of intestinal tissues,
and normalized the endogenous nonenzymatic
antioxidant protein. We observed here that ibrutinib mediated these effects possibly by attenuating the underlying inflammatory cascade such as
TNF-α and NF-κB and by enhancing the protective
mechanism (PI3K/Akt/GSK3-β).
The detrimental effects of DSS can be attributed to the dismantling of the basal epithelium,
which can provoke thinning, atrophy, and necrosis of mucosa, further linked to crypt vanishing of
intestinal goblet cells and infiltration of immune
cells into the colon and intestine [29]. Such infiltration will provoke the release of inflammatory
cytokines such as IL-1β, IL-6, and JNK, which exacerbated inflammatory reactions in intestinal tis-
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Figure 2. Effect of ibrutinib on histopathological injury induced by DSS in mice. A – Effect of ibrutinib on H&E
staining for both small and large intestinal histological features in mice administered with DSS. B – Crypt mitotic
stem cells of intestinal tissue. Photomicrographs were taken at 40× magnification of both small and large intestinal jejunum across all groups. The saline group presents no histopathological changes with tall and intact villi,
while the DSS treated group presents significant histopathological changes followed by severe epithelial atrophy
of villi, enormous inflammatory cells infiltration within lamina propria, vacuolization, and edema both in mucosa
and muscularis. The saline group presents a normal number of stem cells (arrow) in the crypt with no apoptotic
index. The DSS group presents a complete loss of stem cells (arrow) in the crypt with an intense apoptotic index.
The mesalazine group presents renewal of stem cells (arrow) in the crypt with suppressed apoptotic index, while
ibrutinib administration causes the usual proliferation of stem cells (arrow) in the crypt with a reduced apoptotic
index in a dose-dependent manner. The data are expressed as mean ± SEM and were analyzed using one-way
ANOVA followed by Tukey’s multiple comparison test, and n = 7/group. The symbol * shows a difference relative to
the saline group and # shows a difference relative to the DSS group. The data presented are relative to the saline
and the disease group. The symbols *** and ### represent a significant difference values of p < 0.001, while the
symbol ## represents p < 0.01 values for significant differences and # represents p < 0.05
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Figure 3. Ibrutinib attenuated IBD effect by targeting inflammation. A – Western blot analysis
of TNF-α, p-NF-κB, and COX2. The data presented
are relative to β-actin with n = 7 per group and the
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Arch Med Sci 3, 1st May / 2022811

Liangliang Hao, Lina Tariq Alkry, Abdullah Alattar, Muhammad Faheem, Reem Alshaman, Fawad Ali Shah, Shupeng Li

C

DSS

Ibrutinib (6.25 mg/kg)

Ibrutinib (12.5 mg/kg)

Mesalazine (10 mg/kg)

Large intestine

Crypt mitotic stem
cells of intestine

Control

COX-2

Relative integrated density

5
4
3
2
1
0

D

Small intestine
Control
Disease
Ibrutinib (6.25 mg/kg)

DSS

Ibrutinib (6.25 mg/kg)

Ibrutinib (12.5 mg/kg)

Mesalazine (10 mg/kg)

Large intestine

Crypt mitotic stem
cells of intestine

Control

Large intestine
Mesalazine (10 mg/kg)
Ibrutinib (12.5 mg/kg)

p-JNK

Relative integrated density

5
4
3
2
1
0

812

Small intestine
Control
Disease
Ibrutinib (6.25 mg/kg)

Large intestine
Mesalazine (10 mg/kg)
Ibrutinib (12.5 mg/kg)

Figure 3. Cont. The presented images indicate
the immunoreactivity of COX-2 (C) and (D) p-JNK.
Scale bar = 50 μm, magnification 40× with n = 7/
group. The data are presented as means ± SEM
and were analyzed using one-way ANOVA followed
by Tukey’s multiple comparison test. The symbol *
shows a difference relative to the saline group and
#
shows a difference relative to the DSS group. The
symbols *** and ### represent significant difference
values of p < 0.001, while the symbol ## represent
values of p < 0.01 for significant differences and
#
represents p < 0.05. COX2 and JNK show cytoplasmic localization while p-NF-κB can be traced in
the nucleus
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crypt cells, increase of goblet cell emptying, excess
of inflammatory cell infiltration and edema, which
were confirmed by histopathological assessment.
All these histopathological aspects reveal the mucoprotective effects of ibrutinib. Moreover, how
ibrutinib effectively managed these targets needs
to be further investigated.
Our results are in line with previous studies
as DSS administration suppressed the levels of
antioxidant mechanisms such as GSH, GST, and
catalase, and increased the level of LPO [33]. The
ibrutinib group showed a marked increase in the
antioxidant enzymes, while the level of the MDA
was attenuated promisingly. It was found that
treatment with ibrutinib not only increases the
level of the antioxidant enzyme by repressing ROS
production but also reinforces its anti-oxidant potential through inhibition of lipid peroxidation.
ROS production initiated a series of downstream
signaling via the pivotal transcriptional factor NFκB, which regulates several cellular activities such
as inflammation, cell division, apoptosis, differ-

A

B

100

50

0

Catalase [µmol/min/mg]

C

15

10

5

0

3

6
10
Time [days]
Control
Disease
Mesalazine (10 mg/kg)
Ibrutinib (6.25 mg/kg)
Ibrutinib (12.5 mg/kg)

3

6
10
Time [days]
Control
Disease
Mesalazine (10 mg/kg)
Ibrutinib (6.25 mg/kg)
Ibrutinib (12.5 mg/kg)

D

30

300

20

10

0

20

GST [µmol CDNB conjugate/min/mg]

150

LPO [TBRAS mol/min/mg]

GSH [µmol/mg/ml]

sues [30]. NF-κB and c-Jun have been reported to
play a crucial role in inflammation caused in the
colon and significant inhibition of these markers
reduces the pathogenesis of IBD [31]. Moreover,
these mediators are cross-linked to other inflammatory cytokines and chemokine levels and facilitate the migration of immune cells to the colon,
which relates to the pathogenesis of human IBD
[32]. To further reveal the relative role of the inflammatory markers and their associated cascade in our model, we demonstrated that these
markers could exaggerate pathogenicity, as a substantial level of inflammatory cytokines was documented in the disease group and ibrutinib attenuated the level of both histological pathogenesis
and inflammatory mediators. Administration with
ibrutinib alleviated all the physical manifestations
induced by the DSS administration, suggesting
a preferable candidate that protects the mucosa.
Furthermore, treatment with ibrutinib significantly prevented DSS-induced intestinal damage such
as shortening of villi, the disappearance of mitotic
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Figure 4. Effects of ibrutinib on enzymatic and non-enzymatic oxidants. Effects of DSS and ibrutinib on levels of
GSH (A); GST (B); CAT (C), and LPO (D). The data are presented as means ± SEM and were analyzed using one-way
ANOVA followed by Tukey’s multiple comparison test. The symbol * shows a difference relative to the saline group
and # shows a difference relative to the DSS group. The symbols *** and ### represent significant difference values
of p < 0.001, while the symbol ## represents p < 0.01 values for significant differences and # represents p < 0.05
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entiation, and development. DSS can trigger activation of the transcriptional factor NF-κB in intestinal tissue and consequently up-regulate the
expression of several genes, especially those concerned with the production of pro-inflammatory
cytokines [34]. The excessive production of the
proinflammatory cytokines via the positive feedback mechanism further activates NF-κB signaling
and facilitates the swift discharge of mucins from
the goblet cells, rendering them cavitated [35].
As repetitive clinical trials of different protectants
that target a single step in different pharmacological disorders have failed previously, ibrutinib in this
study ameliorated the detrimental effects of hyperuricemia by targeting multiple stages, such as inflammation, oxidative stress, and cellular degeneration. Our results demonstrated that a protectant
acting at different stages may be more advantageous to intervene in the vicious cycles.
As an upstream activator of NF-κB, the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway is implicated in multiple cellular processes,
such as survival, proliferation, differentiation, and
apoptosis, and the PI3K/Akt signaling pathway is
linked to major degenerative diseases. PI3K activation also regulates RhoA kinase, a key regulator
of actin cytoskeleton organization, and may influence both degeneration and protection depending
on the signal strength. Our results showed attenuated expression of PI3K in the DSS, whereas ibru-

tinib treatment enhanced the PI3K/Akt signaling
pathway, suggesting prosurvival signaling.
Conversely, ibrutinib exhibited a protective effect on liver enzymes as a relative safe profile as
no impairment was observed in the liver, further
assisted by serum ALT, AST, ALP, and TB levels. Prospectively, the present study was carried out on
the comparison of study drug ibrutinib with the
standard market drug mesalazine that is mostly
used in IBD.
Overall ibrutinib has attractive potential because of the significant decrease in the hepatic
enzyme level in blood accompanied by reduced
inflammation in intestinal tissues. Similar results
were noted in the present study, with all the effects
alleviating the condition of the treatment group injected with 12.5 mg/kg body weight of ibrutinib.
In conclusion, the current study demonstrated that seven consecutive days of intraperitoneal administration of ibrutinib (6.25 mg/kg and
12.5 mg/kg) alleviated hyperuricemia in an animal
rodent model, and produced significant anti-gout
effects in a dose-dependent manner. In conclusion, IBD activates several proinflammatory mediators including p-NF-κB and is further linked to
ROS generation. Ibrutinib attenuated hyperuricemia-induced oxidative stress and the inflammatory cascade, possibly by modulating the ROS/NF-κB
pathway, potentially accounting for its protective
effects against intestinal necrosis.

Table I. Effect of ibrutinib on liver profile in DSS-induced IBD. Data show the effect of ibrutinib on liver enzymes:
3rd day, 6th day, and 10th day. The data are presented as means ± SEM and were analyzed using one-way ANOVA
followed by Tukey’s multiple comparison test. The symbol * show a difference relative to the saline group and
#
shows a difference relative to the DSS group. The symbols *** and ### represent significant difference values of
p < 0.001, while the symbol ## represents p < 0.01 values for significant differences and # represents p < 0.05
Treatment

TB [mg/dl]

ALT [µ/l]

ALP [mg/dl]

AST [µl]

Control

0.6 ±0.5

55 ±1.4

180 ±2.5

29 ±2.1

Disease

3 day:
rd

3.0 ±0.2***

130 ±2.1***

330 ±4.33***

80 ±6.52***

Mesalazine (10 mg/kg)

0.7 ±0.4#

75 ±0.9#

210 ±2.29##

40 ±7.12##

Ibrutinib (6.25 mg/kg)

0.6 ±0.5

215 ±1.3

#

45 ±2.9#

Ibrutinib (12.5 mg/kg)

0.8 ±0.8##

52 ±1.4##

170 ±2.5#

37 ±4.1#

0.5 ±0.08

58 ±2.3

179 ±3.6

100 ±4.1

Disease

2 ±2.2***

140 ±3.1***

355 ±5.8***

335 ±8.5***

Mesalazine (10 mg/kg)

0.8 ±0.4##

80 ±1.9##

270 ±3.9#

268 ±8.2#

Ibrutinib (6.25 mg/kg)

0.9 ±3.1#

88 ±0.8#

230 ±2.3##

200 ±3.9##

200 ±5.5

177 ±6.1###

##

67 ±0.63

##

6 day:
th

Control

Ibrutinib (12.5 mg/kg)

0.6 ±3.6

###

70 ±3.4

###

###

10th day:
Control

0.5 ±0.08

58 ±2.3

110 ±3.6

110 ±4.1

Disease

3 ±0.5***

122 ±2.3***

160 ±3.8***

300 ±2.5***

Mesalazine (10 mg/kg)

0.6 ±0.4#

70 ±2.5#

141 ±4.5##

158 ±5.2##

Ibrutinib (6.25 mg/kg)

1 ±0.4##

48 ±2.3##

139 ±1.3##

170 ±2.9

Ibrutinib (12.5 mg/kg)

0.6 ±0.3

40 ±4.4

110 ±3.1

140 ±6.1

814

#

###

###
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